The artificial heart is very effective as a bridge to transplant, but the number of people that can be saved with human hearts is limited. A perfect artificial heart could save many more patients. - Robert Jarvik
Impella, Abiomed’s (ABMD) artificial heart, has been in the market since 2008. Impella 2.5 received approval for use in high-risk PCI (Percutaneous Coronary Intervention) in 2015. In 2016 and beyond, the approval got extended to AMICS (Acute Myocardial Infarction and Postcardiotomy Cardiogenic Shock) for Impella 2.5 and its newer versions.
Though sufficient observational data was always